Next Generation Sequencing Software to Help Antibody Engineers, Bioinformaticians Uncover Potential Antibody Therapeutics
SANTA FE, N.M. – December 2, 2021 – OpenEye Scientific and Specifica, Inc., today announced they are releasing jointly developed software to help antibody engineers and bioinformaticians at pharmaceutical and biotechnology companies advance antibody discovery by identifying diverse antibody sets with better properties for downstream therapeutics development.
Read MoreExperts in Biophysics and Molecular Modeling To Advise on Product Development and Strategy
SANTA FE, N.M., USA, – October 28, 2021 – OpenEye Scientific, an industry leader in computational molecular design, has officially introduced its Scientific Advisory Board, which includes experts in the fields of biophysics and molecular modeling.
Read MoreStrategic partnership between Black Diamond and OpenEye aims to accelerate drug discovery efforts through cloud-based molecular dynamics technology
Read MoreSANTA FE, N.M., USA, & KYIV, Ukraine – September 9, 2021 – OpenEye Scientific and Enamine, a leading global provider of billions of new screening compounds to the drug discovery market, are partnering to enable faster and more accurate virtual screening of ultra-large compound libraries through access to innovative software.
Read MoreSANTA FE, N.M. – July 13, 2021 – OpenEye Scientific, an industry leader in computational molecular design, has named Dr. Giovanna Scapin as its newest addition to its Board of Directors.
Read MoreAchievement Demonstrates OpenEye’s Unparalleled Experience Helping Pharmaceutical and Biotechnology Customers Optimize Computing Workloads
Read MoreOrion™ Molecular Design Platform Helps Pharmaceutical, Biotechnology Companies Better Identify, Optimize, and Order Hits and Leads from Mcule’s database
SANTA FE, N.M., & PALO ALTO, Calif. – March 18, 2021 – OpenEye Scientific and Mcule – a leading online marketplace for drug discovery – today announced that OpenEye’s Orion™ molecular design platform now can greatly enhance the ability to search and screen molecules through Mcule’s purchasable compound library.
Read MoreSygnature Accelerates Customers’ Drug Discovery Timelines with Improved Hit Identification, Lead Optimization Capabilities
SANTA FE, N.M., USA, & NOTTINGHAM, UK – 21 January 2021 – OpenEye Scientific and Sygnature Discovery – a world-leading integrated discovery and pre-clinical solutions provider – today announced the adoption of OpenEye’s Orion™ platform to power Sygnature’s computational efforts in molecular design drug discovery solutions.
Read MoreOpenEye Scientific is pleased to announce the release of OpenEye Applications and Toolkits 2020.2, which contains several key upgrades and improved performance.
Read More
